UHG closed Amedisys. There are now 164 mid-market HHAs available for acquisition.

The blockbuster UnitedHealth Group acquisition of Amedisys closed August 14, 2025, after a year-long DOJ antitrust fight that ended with a final consent judgment in December. The price tag — $3.3 billion — and the divestiture order — 164 Amedisys locations — both mark this as the most consequential M&A event in home health in a decade.

What the divestiture means

The DOJ required UHG to divest 164 Amedisys locations to preserve competition in the markets where Amedisys and UHG's existing in-home services overlapped. Those locations are now coming to market through structured divestiture sales. That's an unprecedented concentration of mid-market HHA acquisition targets.

For independent agencies with capital and operational capacity to absorb a tuck-in:

• The targets are real and known — divestiture-mandated sales come with regulatory scrutiny but also with motivated sellers.
• Multi-state agencies can use this to fill geographic gaps in their footprint.
• The deal hygiene matters more than ever (see the BAYADA $17M kickback settlement) — fair-market-value opinions and anti-kickback safe-harbor analysis on every deal.

What it means for agencies in Optum-covered markets

For independent agencies in metros where Amedisys (now Optum) operates, the competitive landscape just got more concentrated. Optum can:

• Steer Medicare Advantage patients from UnitedHealthcare plans to Optum-owned HHAs. Anti-steering rules limit but don't eliminate this.
• Build provider networks that prefer Optum's owned facilities over independents.
• Cross-sell across Optum's care continuum — primary care, urgent care, surgery centers, home health, hospice.

The competitive question for independents: what's your specific value to a referring physician or hospital that an Optum-owned HHA can't match? "We respond faster," "our clinicians stay longer," "our HHCAHPS scores are higher" need to be defensible numbers, not assertions.

What an agency should do

1. Map your overlap with the divestiture markets. Are any of the 164 divestiture locations in your acquisition lane? If yes, get into the process now.
2. Audit your competitive position vs Optum-owned HHAs in your market. If your HHCAHPS scores are below the Optum benchmark, you're losing referrals before the patient ever picks an agency.
3. Strengthen MA payer relationships outside UnitedHealthcare. Humana, Aetna, Centene MA plans are all motivated to maintain independent provider options as Optum consolidates.
4. Tighten care coordination with non-UHG hospitals. The hospital systems competing with Optum are your natural referral allies.

The bigger picture

The Optum integration of Amedisys will take 12–24 months to fully execute. The competitive impact in any individual market will depend on Optum's prioritization — they won't build out every market evenly. The agencies that use this transition window to sharpen their referral relationships and operational metrics will be the ones competing on real differentiators rather than incumbency.

What we built for this

Carelytic's reporting layer surfaces the competitive metrics that matter for these conversations: HHCAHPS scores per branch, clinician retention, time-to-admit on new referrals, payer mix per service area. If you're going to compete with a vertically-integrated payer-provider, you need to know your numbers cold.

The market structure of home health is changing. The agencies that survive and grow in the post-Amedisys era will be the ones with operational rigor — not the ones with the lowest cost structure. Optum can win on cost. Independents win on operations.